Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
The impact of PD-L1 on survival and values of nivolumab, atezolizumab, and pembrolizumab compared with docetaxel in second-line non-small cell lung cancer.
Authors
Helmy M. Guirgis
University of California, Irvine, Orange, CA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Biomarkers and Inflammatory Signatures
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 141)
DOI
10.1200/JCO.2018.36.5_suppl.141
Abstract #
141
Poster Bd #
H1
Abstract Disclosures
Similar Posters
First Author: Jeddeo Paul
Poster
2022 ASCO Annual Meeting
Monitoring PD-L1 expression on circulating stromal cells in blood predicts PFS and OS in patients with metastatic NSCLC treated with PD-L1/PD-1 immunotherapy.
First Author: Jillian Moran
Poster
2019 ASCO Annual Meeting
Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience.
First Author: Bassel Nazha
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre